|Venture Round, 10/2010 ||$6.5M|
|Series C, 10/2013 |
ARCH Venture Partners
Kearny Venture Partners
Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of tumor mutations from cell-free DNA in plasma.